Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study
Published: 12 June 2024| Version 1 | DOI: 10.17632/r6jsy48jjn.1
Contributor:
Siddhartha SoodDescription
Our group previously published 16-week real-world evidence supporting the use of bimekizumab, an interleukin (IL)-17A/IL-17F inhibitor, for treatment of plaque psoriasis. However, long-term data remains limited. Herein, we report 1-year real-world evidence results.
Files
Categories
Dermatology